Cough
Conditions
Brief summary
Cough is a common symptom of respiratory medicine clinic patients, which has complex etiology and wide-ranging. Cough is usually divided into three categories by time: acute cough, subacute cough and chronic cough. Subacute has a 3\ 8 weeks course of disease. Its main etiology is postinfectious cough, which is mostly secondary to viral infection.Considering its overexpression in postinfectious patient, Cysteinyl leukotriene (CysLTs) plays a role in gathering eosinophils to respiratory. The level of FENO has a significant correlation with inflammatory airway eosinophils. While CysLTs overexpressed in vivo, the level of FENO may increase. Montelukast, as CysLTs-receptor-1 antagonists， plays a role of controlling airway inflammation and decrease airway high activity by suppressing the biological activity of CysLTs. It is effective in theory to therapy sub-acute cough by Montelukast, to short the course and to relieve cough symptoms as soon as possible. The aim is to research whether FENO can be used as a biomarker to optimized treatment regimen of sub-acute cough.
Detailed description
Patients in electrical treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
Interventions
DRUGMontelukast
Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
Sponsors
Beijing Chao Yang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Cough is the main or only clinical symptom and was persistent for 3-8 weeks * Chest X-ray reveals no noticeable pathological changes * 18 year old, regardless of gender and ethical background * Not taking angiotensin-converting enzyme inhibitor * Patients must join the programme voluntarily and are able to attend examination and follow-up sessions
Exclusion criteria
* Patients diagnosed with allergic rhinitis, chronic nasosinusitis or bacterial respiratory tract infections * Patients diagnosed with severe reportorial disease of other severe systemic disease * Patients who are allergic to any drugs to be tested * Patients who are non-cooperative during examination sessions or other steps of the trial * Patients who are not able to or refuse to sign consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Leicester Cough Questionnaire(LCQ) total and domain scores at 10 days post randomisation | 10 days |
Secondary
| Measure | Time frame |
|---|---|
| cough visual analogue scale scores post randomisation(area under the curve) | 10 days |
| Change in Leicester Cough Questionnaire(LCQ) physical,psychological and social domain scores at 10 days post randomisation | 10 days |
Countries
China
Contacts
Primary ContactKewu Huang, M.D.
Backup ContactMin Liu, Master
Outcome results
None listed